Purpose: Extracellular matrix metalloproteinase inducer (EMMPRIN) promotes angiogenesis through matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) production. We investigated the expression levels of EMMPRIN and correlated these levels with VEGF, MMP-1 and MMP-9 in proliferative diabetic retinopathy (PDR). In addition, we examined the expression of EMMPRIN in the retinas of diabetic rats and the effect of EMMPRIN on the induction of angiogenesis regulatory factors in human retinal microvascular endothelial cells (HRMECs). Methods: Vitreous samples from 40 PDR and 19 non-diabetic patients, epiretinal membranes from 12 patients with PDR, retinas of rats and HRMECs were studied by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, Western blot analysis, zymography analysis and RT-PCR. Results: We showed a significant increase in the expression of EMMPRIN, VEGF, MMP-1 and MMP-9 in vitreous samples from PDR patients compared with non-diabetic controls (p < 0.0001; p = 0.001; p = 0.009; p < 0.0001, respectively). Significant positive correlations were found between the levels of EMMPRIN and the levels of VEGF (r = 0.38; p = 0.003), MMP-1 (r = 0.36; p = 0.005) and MMP-9 (r = 0.46; p = 0.003). In epiretinal membranes, EMMPRIN was expressed in vascular endothelial cells and stromal cells. Significant increase of EMMPRIN mRNA was detected in rat retinas after induction of diabetes. EMMPRIN induced hypoxia-inducible factor-1a, VEGF and MMP-1 expression in HRMEC. Conclusions: These results suggest that EMMPRIN/MMPs/VEGF pathway is involved in PDR angiogenesis.
Introduction
Ischaemia-induced angiogenesis, a process by which new blood vessels are formed from pre-existing ones, is the pathological hallmark feature in the ocular microenvironment of patients with proliferative diabetic retinopathy (PDR). This process takes place as a consequence of an angiogenic switch, which allows the sprouting of blood vessels within tissues (Hanahan & Folkman 1996; Carmeliet 2003) . Angiogenesis is a multistep process requiring the degradation of the basement membrane and the extracellular matrix (ECM), endothelial cell migration, endothelial cell proliferation and capillary tube formation (Deryugina & Quigley 2010) . To form new blood vessels, activated endothelial cells must degrade the basement membrane of the original vessel and remodel the ECM around neovascular sites (Deryugina & Quigley 2010) . Proteases, such as matrix metalloproteinases (MMPs), have been implicated in this process (Deryugina & Quigley 2010) . In the ocular microenvironment of patients with PDR, the levels of the MMPs MMP-1, MMP-7 and MMP-9 are increased dramatically (Abu El-Asrar et al. 2013 ). This upregulation of MMPs is linked to angiogenesis and progression of PDR. In addition to removing the physical barrier to new vessel growth, MMPs may facilitate pathologic neovascularization through stimulation of the production of vascular endothelial growth factor (VEGF) (Hollborn et al. 2007 ) and the proteolytic release of VEGF from the ECM-associated reservoirs (Hawinkels et al. 2008; Ebrahem et al. 2010) , resulting in increased VEGF bioavailability and triggering the VEGF-driven angiogenic switch.
Among the angiogenic regulators, VEGF is known to be a major factor in PDR that promotes neovascularization and vascular leakage (Spranger & Pfeiffer 2001) . Vascular endothelial growth factor (VEGF) exerts its angiogenic effects by binding to its main receptor VEGFR-2 (KDR) (Shibuya 2006) . Hypoxia-inducible factor-1a (HIF-1a) is a transcription factor that accumulates in cells during hypoxia and it heterodimerizes with the constitutively expressed HIF-1b subunit, triggering the activation of many genes encoding proteins that regulate angiogenesis, such as VEGF (Huang et al. 1998; Yamakawa et al. 2003; Sayed & Mahmoud 2016) . Hypoxia-inducible factor-1a (HIF-1a) may be a target for inflammatory events in diabetic retinopathy (Gao et al. 2016) . Angiogenesis depends on multiple factors, and when the activity of one angiogenic factor such as VEGF is suppressed, the expression of other angiogenic factors may appear (Dorrell et al. 2007 ). Therapeutic regulation of angiogenesis has emerged as an attractive approach for the treatment of PDR (Salam et al. 2011) . To aid the progress of these strategies, a more comprehensive understanding of the molecules that regulate angiogenesis in PDR is of value to identify additional therapeutic targets.
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as basigin and cluster of differentiation (CD) 147, is a highly glycosylated member of the immunoglobulin superfamily. Increased EMMPRIN expression in cancer tissue is associated with increased synthesis of several MMPs and VEGF, increased angiogenesis, clinically aggressive behaviour and poor prognosis (Van den Oord et al. 1997; Tang et al. 2005; Yan et al. 2005; Weidle et al. 2010) . Therefore, EMMPRIN probably functions as an upstream modulator of MMPs and VEGF production in the tumour local environment. In the context of inflammatory diseases, EMMPRIN is relatively understudied (Agrawal & Yong 2011) , although it has been suggested as a target for intervention with neutralizing antibodies in animal models of asthma-mediated lung inflammation (Gwinn et al. 2006 ) and experimental autoimmune encephalitis as a model of multiple sclerosis (Agrawal et al. 2012) . Within the eye, EMMPRIN expression has been detected in the corneal and conjunctival epithelium, the endothelium, and in the stromal keratocytes, the retinal pigment epithelium, several retinal layers and nerve fibres in the optic nerve head. In addition, solubilized EMM-PRIN was detected in aqueous humour and vitreous samples and in tear fluids (M€ a€ att€ a et al. 2006) .
Given the key roles of EMMPRIN in angiogenesis, we hypothesized that EMMPRIN may be involved in the pathogenesis of PDR. To test this hypothesis, we investigated the expression of EMMPRIN in the vitreous fluid and epiretinal fibrovascular membranes from patients with PDR and correlated EMMPRIN levels with the levels of the angiogenic factor VEGF and the MMPs, MMP-1 and MMP-9. In addition, we investigated the expression of EMMPRIN in the retinas of diabetic rats. Finally, we evaluated the effect of EMMPRIN on the induction of angiogenesis regulatory factors in human retinal microvascular endothelial cells (HRMECs).
Materials and Methods

Vitreous samples and epiretinal membrane specimens
We studied undiluted vitreous fluid samples obtained from 40 patients with PDR during pars plana vitrectomy as described (Abu El-Asrar et al. 2015) . The severity of retinal neovascular activity was graded at the time of vitrectomy on the basis of previously published criteria. Neovascularization was considered active if there were visible new vessels on the retina or optic disc present within the epiretinal membranes. Neovascularization was considered inactive if only non-vascularized, white fibrotic epiretinal membranes were present (Aiello et al. 1994) . Active PDR was present in 20 patients, and inactive PDR was present in 20 patients. The total PDR group consisted of a subgroup of 15 patients who had insulin-dependent diabetes mellitus and another subgroup of 25 patients who had non-insulin-dependent diabetes mellitus. The non-diabetic subject group consisted of 19 patients who had undergone vitrectomy for the treatment of rhegmatogenous retinal detachment with no proliferative vitreoretinopathy. Epiretinal fibrovascular membranes were obtained from 12 patients with PDR during pars plana vitrectomy for the repair of tractional retinal detachment. Membranes were fixed for 2 hr in 10% formalin solution and embedded in paraffin.
The study was conducted according to the tenets of the Declaration of Helsinki. All the patients were candidates for vitrectomy as a surgical procedure. All patients signed a preoperative informed written consent and approved the use of the excised epiretinal membranes and vitreous fluid for further analysis and clinical research. The study design and the protocol were approved by the Research Centre and Institutional Review Board of the College of Medicine, King Saud University.
Rat streptozotocin-induced diabetes model
All procedures with animals were performed in accordance with the ARVO statements for the use of animals in ophthalmic and vision research and were approved by the Institutional Animal Care and Use Committee of the College of Pharmacy, King Saud University. Adult male Sprague Dawley rats, 8-9 weeks of age weighting in the range of 220-250 g, were overnight fasted and a single high dose of streptozotocin (STZ; 65 mg/kg in 10 mM sodium citrate buffer, pH 4.5; Sigma, St. Louis, MO, USA) was injected intraperitoneally. Equal volumes of citrate buffer were injected into control animals. Measurement of blood glucose concentrations and body weight was started 3 days after injection of STZ. Diabetes was confirmed by assaying the glucose concentration in blood taken from the tail vein. Rats with glucose levels >250 mg/dl were categorized as diabetic. After 4 weeks of diabetes, animals were anesthetized by intraperitoneal injection of an overdose of chloral hydrate and killed by decapitation. Retinas were dissected, flash frozen and stored at À70°C until use. Similarly, retinas were obtained from age-matched non-diabetic control rats.
Cell culture
Primary HRMECs were purchased from Cell Systems Corporation (Kirkland, Washington, USA) and maintained in complete serum-free media (Cat. No. SF-4Z0-500, Cell System Corporation) supplemented with recombinant RocketFuel (Cat No. SF-4Z0-500, Cell System Corporation), CultureBoost (Cat. No. 4CB-500, Cell System Corporation) and antibiotics (Cat. No. 4Z0-643, Cell System Corporation) at 37°C in a humidified atmosphere with 5% 150 CO 2 as described (Abu El-Asrar et al. 2015) . Following starvation, HRMECs were either left untreated or treated with 10 ng/ml of recombinant active human (rh) EMM-PRIN protein fragment (Cat. No. ab155636, Abcam, Cambridge, UK) for 24 hr and then harvested.
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assay (ELISA) kits for human EMMPRIN (Cat No: ab119592), human MMP-1 (Cat No: ab100603) and human MMP-9 (Cat No: ab100610) were purchased from Abcam. An ELISA kit for human VEGF (Cat No: SVE00) was purchased from R&D Systems, Minneapolis, MN, USA. The minimum detection limits for the EMMPRIN, MMP-1, MMP-9 and VEGF ELISA kits were 2 pg/ml, 8 pg/ml, 10 pg/l and 9 pg/ml, respectively. The ELISA plate readings were done using a Stat Fax-4200 microplate reader from Awareness Technology, Inc., Palm City, FL. The quantification of human EMM-PRIN/CD147, MMP-1, MMP-9 and VEGF in vitreous fluids was determined using ELISA kits according to the manufacturer's instructions as described (Abu El-Asrar et al. 2015) .
Western blot analysis
Human retinal microvascular endothelial cells (HRMECs) were lysed after harvest with RIPA buffer [50 mM TrisHCl (pH 7.5), 150 mM NaCl, 1% (v/v) Nonidet P40 (NP40), 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor 'Complete without EDTA' (Roche, Mannheim, Germany)]. Wholecell extracts from different treated groups were centrifuged at 12 000 9 g for 10 min at 4°C. The supernatants were collected and protein concentrations were measured with the use of DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 8-10% gels and transferred onto nitrocellulose membranes (BioRad Laboratories). To determine the expression of EMMPRIN in the vitreous samples, equal volumes (15 ll) of vitreous samples were boiled in Laemmli's sample buffer (1:1, v/v) under reducing conditions for 10 min and analysed as described (Abu El-Asrar et al. 2015) . Blots were then incubated at 4°C overnight using the following primary antibodies: anti-HIF-1a (1:500; sc 53546, Santa Cruz, Biotechnology Inc., Santa Cruz, CA, USA), anti-MMP-1 (1:1000, MAB 901, R&D Systems), anti-VEGF (1:500, Cat. No. MAB293 R&D Systems) and anti-EMMPRIN (1:1000, Cat. No. ab108317, Abcam) as described (Abu ElAsrar et al. 2015) .
Immunohistochemical staining
For CD31 and a-smooth muscle actin (a-SMA), antigen retrieval was performed by boiling the sections in citrate-based buffer (pH 5.9-6.1; BOND Epitope Retrieval Solution 1; Leica, Newcastle upon Tyne, UK) for 10 min. For CD45 and EMMPRIN detection, antigen retrieval was performed by boiling the sections in Tris-EDTA buffer (pH 9; BOND Epitope Retrieval Solution 2; Leica) for 20 min. Subsequently, the sections were incubated for 60 min with mouse monoclonal anti-CD31 (ready to use; clone JC70A; Dako, Glostrup, Denmark), mouse monoclonal anti-CD45 (ready to use; clones 2B11+PD7/ 26; Dako), mouse monoclonal anti-a-SMA (ready to use; clone 1A4; Dako) and rabbit monoclonal anti-EMMPRIN antibody (1:200; ab108317, Abcam). Optimal working concentrations and incubation times for the antibodies were determined earlier in pilot experiments on glioblastoma sections as described (Abu El-Asrar et al. 2013 . Omission or substitution of the primary antibody with an irrelevant antibody from the same species (rabbit monoclonal anti-human oestrogen receptor a; ready to use; clone EPI, Dako) and staining with chromogen alone were used as negative controls.
Real-time reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from retina using TRI reagent (Ambion, TX, USA), according to manufacturer's protocol. cDNAs were synthesized from 1 lg RNA, using an high capacity cDNA reverse transcription kit (Applied Biosystem, Carlsbad, CA, USA ) following the manufacturer's instructions. Realtime RT-PCR was performed using a SYBR green PCR master mix. The PCR primers for rat were as follows: EMM-PRIN/CD147 forward 5 0 -ACAGCAG TGGCATTGACATC-3 0 and reverse 5 0 -TGTTCCGATTTCTTTCCCAC-3 00 and b-actin forward 5 0 -CCTCTATGC-CAACACAGT GC-3 0 and reverse 5 0 -CATCGTACTCCTGCTTGCTG-3 0 . The standard PCR conditions included 2 min at 50°C and 10 min at 95°C followed by 40 cycles of extension at 95°C for 15 s and one min at 60°C. Threshold lines were automatically adjusted to intersect amplification lines in the linear portion of the amplification curves and cycle to threshold (Ct) values were recorded automatically. Data were normalized with b-actin mRNA levels (housekeeping gene) and the fold change in gene expression relative to normal was calculated using the ddCt method (Livak & Schmittgen 2001) .
Zymography
Gelatinolytic levels of MMP-2 and MMP-9 were estimated in culture media by zymography technique. The samples (5-20 ll) were electrophoresed under non-reducing conditions onto 10% SDS-PAGE polymerized with 1 mg/ml gelatin. After washing the gel with 2.5% Triton-X-100, it was incubated overnight at 37°C in substrate buffer containing 50 mM TrisHCl, pH 8.0, 5 mM CaCl2 and 0.02% NaN. The gel was stained with Coomassie Blue stain (0.5% Coomassie Blue R-250, 5% methanol and 10% acetic acid), followed by destaining (5% methanol, 10% acetic acid). The image was taken with the GENESYS (version 1.2.0.0) software on a G: Box machine (Syngene, Cambridge, UK) and signal intensity of bands (for MMP-9:~92 kDa and for MMP-2:~70 kDa) was quantified using the Gene Tools software (Syngene). Fig. 1 ). When patients with PDR were divided into those with active neovascularization and those with quiescent disease, the mean level of EMMPRIN in the vitreous samples from patients with active PDR [1464.9 pg/ml (592.8 pg/ ml)] was significantly higher than in the patients with inactive PDR [1031.8 pg/ ml (393.2 pg/ml)] (p = 0.015; MannWhitney U-test).
Vascular endothelial growth factor (VEGF) was detected in 15 of 19 (78.9%) vitreous samples from non-diabetic control patients and in 29 of 40 (72.5%) vitreous samples from patients with PDR. Mean VEGF level in vitreous samples from PDR patients [484.9 pg/ ml (893.9 pg/ml)] was significantly higher than the mean level in nondiabetic control patients [39.5 pg/ml (36.3 pg/ml)] (p = 0.001; Mann-Whitney U-test; Fig. 1) . The mean VEGF level in the vitreous samples from patients with active PDR [781.3 pg/ml (1186.1 pg/ml)] was significantly higher than in the patients with inactive PDR [188.6 pg/ml (221.0 >pg/ml)] (p = 0.03; Mann-Whitney U-test). MMP-1 was not detected in vitreous samples from nondiabetic control patients. However, MMP-1 was detected in 12 of 40 (30%) vitreous samples from patients with PDR. The mean MMP-1 level in vitreous samples from PDR patients [25.9 pg/ml (51.7 pg/ml)] was significantly higher than the mean level in non-diabetic control patients (p =0.009; Mann-Whitney U-test; Fig. 1 ). The mean level of MMP-1 did not differ significantly between patients with active PDR [42.7 pg/ml (67.2 pg/ml)] and patients with inactive PDR [9.1 pg/ ml (19.6 pg/ml)] (p = 0.102; MannWhitney U-test).
In comparison with MMP-1, about a thousand-fold higher levels of MMP-9 were detected in PDR samples. MMP-9 was detected in all vitreous samples from patients with PDR and non-diabetic control patients. The mean MMP-9 level in vitreous samples from PDR patients [17790.3 pg/ml (10679.1 pg/ml)] was significantly higher than the mean level in Fig. 1 . Comparison of mean extracellular matrix metalloproteinase inducer (EMMPRIN), vascular endothelial growth factor (VEGF), matrix metalloproteinase-1 (MMP-1) and MMP-9 levels in vitreous fluid samples between patients with proliferative diabetic retinopathy (n = 40) and control patients without diabetes (RD; n = 19). *The difference between the two means was statistically significant at 5% level of significance.
non-diabetic control patients [7509.5 pg/ ml (5028.6 pg/ml)] (p < 0.0001; MannWhitney U-test; Fig. 1 ). The MMP-9 levels varied widely and the mean level of MMP-9 did not differ significantly between patients with active PDR [20058.0 pg/ml (10545.6 pg/ml)] and patients with inactive PDR [5522.5 pg/ml (10585.4 pg/ml)] (p = 0.137; MannWhitney U-test).
Correlations
Significant positive correlations were found between the vitreous fluid levels of EMMPRIN and the levels of VEGF (r = 0.38; p = 0.003), MMP-1 (r = 0.36; p = 0.005) and MMP-9 (r = 0.46; p = 0.003). Significant positive correlations were observed between vitreous fluid levels of MMP-9 and levels of VEGF (r = 0.27; p = 0.036) and MMP-1 (r = 0.38; p = 0.003).
Western blot analysis of vitreous samples
With the use of Western blot analysis of equal volumes (15 lL) of vitreous samples, we confirmed that EMM-PRIN was expressed in vitreous samples from patients with PDR (n = 12) and control patients without diabetes (n = 12).
Extracellular matrix metalloproteinase inducer (EMM-PRIN) protein migrated as one protein band on SDS-PAGE when immunoblotted and analysed with the specific antibody at approximately 52 kDa. Densitometric analysis of the bands demonstrated a significant increase in EMMPRIN in vitreous samples from PDR patients compared to control patients (p = 0.005; Mann-Whitney U-test; Fig. 2 ).
Immunohistochemical analysis of epiretinal membranes
To identify possible sources of vitreous fluid EMMPRIN, epiretinal fibrovascular membranes from patients with PDR were studied by immunohistochemical analysis. No staining was observed in the negative control studies (Fig. 3A) . All membranes showed blood vessels that were positive for the endothelial cell marker (CD31; Fig. 3B ). Strong immunoreactivity for EMMPRIN was present in all membranes and was noted in vascular endothelial cells, intravascular leucocytes, stromal cells and stromal spindle-shaped cells (Fig. 3C,D) . In serial sections, the distribution and morphology of stromal cells expressing EMM-PRIN were similar to those of cells expressing the leucocyte common antigen CD45 (Fig. 3E) . In addition, the distribution and morphology of spindleshaped stromal cells expressing EMM-PRIN (Fig. 3C) were similar to those of spindle-shaped stromal cells expressing the myofibroblast marker a-SMA (Fig. 3F) .
EMMPRIN induces upregulation of angiogenesis regulatory factors in HRMEC
To confirm the positive correlation between the vitreous fluid levels of EMMPRIN and the levels of VEGF, MMP-1 and MMP-9, we performed short-term induction experiments on HRMEC with EMMPRIN. HRMECs were stimulated for 24 hr with 10 ng/ ml rh EMMPRIN, and we compared the levels of expression of HIF-1a, VEGF and MMP-1 in the whole-cell extracts by Western blot analysis. We found that EMMPRIN treatment increased the expression of HIF-1a, VEGF and MMP-1 (Fig. 4) . Gelatin zymography analysis of the 24 hr in vitro culture media showed that EMMPRIN treatment did not induce major changes in MMP-2 and MMP-9 expression levels (data not shown).
Severity of hyperglycaemia and effect of diabetes on retinal mRNA levels of EMMPRIN in experimental rats
After induction of diabetes with a single dose of STZ, the body weights of the diabetic rats were significantly lower and their blood glucose values were more than fourfold higher compared with age-matched normal control rats [169 g (18 g ) versus 253 g (22 g) and 467 mg/dl (28 mg/dl) versus 107 mg/dl (10 mg/dl), respectively]. Retinal mRNA levels of EMMPRIN in the diabetic rats were increased by about twofold as compared to nondiabetic control rats (p = 0.02; Mann-Whitney U-test; Fig. 5 ). This result is in line with the threefold increase of EMMPRIN protein in human samples.
Discussion
In the present study, we showed for the first time that EMMPRIN was significantly upregulated in the vitreous fluid from patients with PDR and in the retinas of diabetic rats. Our subgroup analysis showed that the vitreous levels of EMMPRIN were higher in PDR eyes with active neovascularization compared with the eyes with quiescent disease. In addition, we found a significant positive correlation between the vitreous fluid levels of EMMPRIN and those of the MMPs MMP-1 and MMP-9 and the angiogenic biomarker VEGF, a key angiogenic factor in PDR (Spranger & Pfeiffer 2001) . Using immunohistochemistry, we demonstrated that EMMPRIN was localized in vascular endothelial cells, leucocytes expressing the leucocyte common antigen CD45 and myofibroblasts in epiretinal fibrovascular membranes from patients with PDR. Cancer cells overexpressing EMM-PRIN stimulate upregulation of VEGF (Tang et al. 2005 (Tang et al. , 2006 and the MMPs MMP-1, MMP-2 and MMP-9 (Tang et al. 2004 (Tang et al. , 2005 (Tang et al. , 2006 Millimaggi et al. 2007 ). Interestingly, EMMPRIN also induced its own gene expression (Tang et al. 2004) . Increased expression of membrane-associated EMMPRIN in tumour cells was accompanied by an MMP-dependent generation of a soluble form of EMMPRIN, representing a proteolytic cleavage product lacking the carboxyl terminus. Soluble EMM-PRIN is functional in stimulating MMP expression in fibroblast and endothelial cells (Tang et al. 2004 ). These findings suggest that increased expression of MMPs in the ocular microenvironment of patients with PDR may result in proteolytic cleavage of membrane-associated EMMPRIN, releasing soluble EMMPRIN. Soluble EMMPRIN in turn acts in a paracrine fashion to further stimulate the production of VEGF, MMPs and additional EMMPRIN, which consequently contributes to PDR angiogenesis and progression. In the present study, we detected simultaneous expression of EMM-PRIN, VEGF, MMP-1 and MMP-9 in the vitreous fluid from patients with PDR. There were significant positive correlations between the levels of EMMPRIN and the levels of VEGF, MMP-1 and MMP-9. These findings are in accordance with previous reports that demonstrated active involvement of EMMPRIN in the upregulation of VEGF (Tang et al. 2005; Bougatef et al. 2009 ), MMP-1 (Tang et al. 2004; Millimaggi et al. 2007 ) and MMP-9 (Tang et al. 2004 (Tang et al. , 2005 (Tang et al. , 2006 ). In the current study, EMM-PRIN was localized in vascular endothelial cells and stromal cells in PDR epiretinal fibrovascular membranes. Similarly, in previous studies, we demonstrated VEGF (Abu El-Asrar et al. 2007) and MMP-9 (Abu El-Asrar et al. 2013 ) localization in vascular endothelial cells and stromal cells in epiretinal membranes from patients with PDR. The coexpression of these angiogenesis regulatory factors in the ocular microenvironment of patients with PDR suggests a crosstalk between these factors in the pathogenesis of PDR angiogenesis and progression and that the coexpression of these factors is mechanistically interrelated.
Angiogenesis involves the activation and invasion of endothelial cells through their basement membrane, migration to distal sites and tube formation. It has been demonstrated that EMMPRIN contributes to each of these events and promotes the angiogenic phenotype in human endothelial cells in vitro (Millimaggi et al. 2007; Bougatef et al. 2009; Chen et al. 2009 ). In addition, EMMPRIN has a potent anti-apoptotic effect on endothelial cells (Chen et al. 2009 ). Several vascular regulatory proteins and growth factors have been shown to be activated or upregulated by EMMPRIN in endothelial cells. Extracellular matrix metalloproteinase inducer selectively upregulated the expression of VEGF, VEGFR-2, HIF-1a and HIF-2a in human dermal microvascularendothelial cells (Bougatef et al. 2009 ).Itwas demonstrated that EMMPRIN-induced endothelial cell migration and tube formation is mediated by VEGF/VEGFR-2 signalling (Bougatef et al. 2009 ). Furthermore, EMMPRIN induced upregulation of MMP-1, MMP-2, and MMP-9 in human umbilical vein endothelial cells (Millimaggiet al.2007; Chenet al. 2009 ). Recently, it was demonstrated that EMMPRIN enhanced VEGF-induced VEGFR-2 phosphorylation in human dermal microvascular endothelial cells, downstream signalling of the VEGFinduced pathway and consequently cell migration (Khayati et al. 2015 ). In the current study, we confirmed that stimulation with EMMPRIN caused small upregulation of HIF-1a, VEGF and MMP-1inHRMEC. Additionally, EMM PRIN was demonstrated to recruit bone marrow-derived cells, which contribute to tumour neovascularization (Chen et al. 2015) . In previous studies, we demonstrated that bone marrow-derived endothelial precursor cells contribute to neovascularizationinPDR (AbuEl-Asrar et al. 2010 .
Recent data show that in addition to its well-characterized role in cancer, EMMPRIN activity may represent an important determinant in the pathogenesis of organ fibrosis (Kato et al. 2011; Yan et al. 2015; Hasaneen et al. 2016 ). Fibroblasts overexpressing EMMPRIN had a significant increase in cell proliferation and migration and showed a significantly increased expression of a-SMA, a marker of differentiation to myofibroblasts. Furthermore, EMM-PRIN promoted fibroblasts resistance to apoptosis (Hasaneen et al. 2016) . Extracellular matrix metalloproteinase inducer and a-SMA were colocalized to the same cells in epiretinal fibrovascular membranes from patients with PDR, thus supporting a role for EMMPRIN in the differentiation of myofibroblasts in vivo.
In conclusion, we suggest that the EMMPRIN/MMPs/VEGF pathway is involved in PDR angiogenesis and progression. Consequently, the development of effective therapeutic interventions to inhibit EMMPRIN (Gwinn et al. 2006; Agrawal et al. 2012) would provide a novel and potentially powerful alternative to current treatments. . Gene expression of Extracellular matrix metalloproteinase inducer (EMM-PRIN) in the retinas was quantified by RT-PCR using the specific primer given in the materials and methods section and was adjusted to the mRNA level of b-actin in each sample. Diabetes induced a significant increase in the gene expression of EMMPRIN in the retinas of diabetic rats (D) (n = 6) compared to non-diabetic controls (N) (n = 6). Results are expressed as mean AE standard deviation. *The difference between the two means was statistically significant at 5% level of significance.
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